Introduction
============

Pancreatic cancer (PC) is primarily associated with diabetes, obesity, smoking and genetic conditions, such as germline pathogenic variants and somatic pathogenic variants in DNA damage repair (DDR) genes ([@b1-ol-0-0-11575],[@b2-ol-0-0-11575]). Jaundice, weight reduction, back or abdominal pain, deep-colored urine, pale-colored stools and anorexia are the typical symptoms ([@b3-ol-0-0-11575]). However, at diagnosis, the cancer has usually metastasized ([@b4-ol-0-0-11575],[@b5-ol-0-0-11575]). The mortality rate of PC is high and there were 411,600 PC-associated deaths globally in 2015 ([@b6-ol-0-0-11575]). Pancreatic adenocarcinoma (PAAD) is a common type of PC, accounting for \~85% of all PC cases ([@b7-ol-0-0-11575]). The survival rate of PAAD is very low and the 5-year survival rate was 5% in 2015 ([@b8-ol-0-0-11575]). A few prognostic indicators are now available for PC, such as C-reactive protein/albumin ratio and neutrophil/lymphocytes ratio ([@b9-ol-0-0-11575],[@b10-ol-0-0-11575]). Therefore, it is of great importance to investigate the prognostic factors of PAAD for improved prediction.

It has been hypothesized that DNA methylation may provide a link between environmental factors contributing to cancer development ([@b11-ol-0-0-11575]). The stability of the genome and gene expression levels are primarily maintained by a pre-determined pattern of DNA methylation ([@b12-ol-0-0-11575]). It has been reported that DNA hypermethylation has prognostic value and acts as independent predictor of survival in other cancer types, such as head and neck cancer ([@b13-ol-0-0-11575]). A previous study reported an association between abnormal methylation of the *Reprimo* gene and genetic instability and poor survival following surgical resection in patients with PC ([@b14-ol-0-0-11575]). Hypermethylation of Cyclin D2 is also frequently observed in PC ([@b15-ol-0-0-11575]). Meanwhile, another study reported a significant difference in the hypermethylation frequency of *ALX4, BNC1, HIC1, SEPT9V2,SST, TFPI2* and *TAC1* between PAAD samples of stage I, II, III and IV, and these genes are significantly associated with distant metastasis of PAAD ([@b16-ol-0-0-11575]).

A number of clinical markers of PAAD survival have been recognized, including stage at diagnosis, grading and performance status and the treatment received, such as resection versus no resection and chemotherapy vs. no chemotherapy ([@b17-ol-0-0-11575]--[@b20-ol-0-0-11575]). It has also been reported that obesity and smoking are associated with a less favorable prognosis of PC ([@b21-ol-0-0-11575]). Cigarette smoking is associated with the development of \~20% of PC cases and is therefore a consistent risk factor ([@b22-ol-0-0-11575]). Bioinformatic databases may serve as a valuable tool to further our understanding of the molecular mechanisms underpinning the prognosis of patients with cancer.

The present study aimed to explore the aberrant methylation of genes associated with prognosis of patients with PAAD. The methylation data of genes associated with PAAD were obtained from The Cancer Genome Atlas (TCGA) database and screened for differentially methylated genes (DMGs) associated with prognosis. Subsequently, these data were used to construct a risk score system, which may be effective in predicting the prognosis of patients with PAAD.

Materials and methods
=====================

### Datasets

The methylation data for the training dataset was obtained from the TGCA database (accessed on 5^th^ June 2018; [cancer.gov/tcga](cancer.gov/tcga)), which were based on the Illumina Infinium Human Methylation 450 BeadChip platform. There were a total of 184 samples, 168 of which included prognostic information \[mean age, 64.89±11.24 years (range: 40--88); male: female, 94/75; average overall survival time, 17.09±15.22 months; death: survival, 88/80\]. The methylation data for the validation training set was obtained from the European Bioinformatics Institute ArrayExpress database (ebi.ac.uk/arrayexpress/), specifically the E-MTAB-5008 and E-MTAB-5571 datasets. The E-MTAB-5008 dataset consisted of 29 PAAD samples with prognostic information and the E-MTAB-5571 dataset consisted of 24 PAAD samples which prognostic information. Both of these datasets were sequenced on the platform of Illumina Infinium Human Methylation 450 BeadChip.

### Screening of DMGs

To screen genes associated with PAAD prognosis, samples in the TCGA dataset were divided into less favorable prognosis (defined as a survival time \<6 months and death) and more favorable prognosis (defined as survival time \>24 months or alive) groups based on a previously described grouping method ([@b23-ol-0-0-11575]). The methylation loci of genes associated with PAAD prognosis were annotated and combined with the platform annotation information on the Illumina Infinium Human Methylation 450 BeadChip platform and the loci within CpG islands of the genes were selected and used for the following analysis. Using the limma package in R (version 3.34.7) ([@b24-ol-0-0-11575]), the DMGs between the less favorable prognosis and more favorable prognosis groups were screened according to the following criteria: \|log fold change\| \>0.263 and false discovery rate (FDR) \<0.05. Then, the Kernel density curve of the DMGs was generated by calculating the Log 2 (FC).

### Identification of co-methylated genes based on Weighted Gene Co-expression Network Analysis (WGCNA)

Co-methylation analysis using the WGCNA package (version 1.63) ([@b25-ol-0-0-11575]) in R was performed on genes located in CpG islands to identify differentially methylated CpG genes (DMCpGs). The sets of CpG genes with highly related methylation levels under the same biological process or in different tissues were considered as modules. The modules which had a significant association with the methylation levels were identified. The DMCpGs were mapped to the modules and the significant enrichment parameters and fold enrichment were calculated using a hypergeometric test ([@b26-ol-0-0-11575]). The DMCpGs enriched modules were screened under the following criteria: P\<0.05 and a fold enrichment value of \>1 was considered to indicate a statistically significant difference. Genes in DMCpGs enriched modules were recognized as key methylation genes and were analyzed using Gene Ontology (GO) enrichment analysis ([@b27-ol-0-0-11575]) using the Database for Annotation, Visualization and Integrated Discovery (version 6.8) ([@b28-ol-0-0-11575]).

To meet scale-free network distribution, the weighting parameter 'power' in WGCNA algorithm was explored. When the square of the correlation coefficient between log(k) and log\[p(k)\] reached 0.9, the corresponding value of parameter 'power' (power=7) was selected. Under power=7, the mean connectivity of genes was calculated to be 1. Subsequently, the adjacency matrix elements were serialized, and the topological overlap matrix was calculated to evaluate the correlation of gene methylation levels and obtain a system clustering tree. According to the standards of hybrid dynamic shear tree, pruning height (cutHeight) and the minimum number of module genes (minSize) separately were set as 0.95 and 50.

### Correlation analysis for the expression levels and methylation levels of key methylated genes

The expression and methylation levels of key methylation genes in matched training PAAD samples were collected and correlation analysis was performed. Pearson correlation coefficients (PCCs) were calculated and the cor.test function ([stat.ethz.ch/R-manual/R-devel/library/stats/html/cor.test.html](stat.ethz.ch/R-manual/R-devel/library/stats/html/cor.test.html)) in R Software was used ([@b29-ol-0-0-11575],[@b30-ol-0-0-11575]). PCCs of single genes were also calculated and the genes with a negative correlation between expression level and methylation level were selected as key methylation genes for subsequent analyses. P\<0.05 was considered to indicate a statistically significant difference.

### Identification of the methylated genes associated with prognosis

Key methylation genes with a negative correlation between expression level and methylation level were further analyzed for prognosis associated genes. Univariate Cox regression analysis was performed to identify prognosis associated methylation genes using the survival package (version 2.41--1) in R ([@b31-ol-0-0-11575]). P\<0.05 was considered to indicate a statistically significant difference.

### Construction of risk score prognostic prediction system

The optimal combination of prognosis related methylation genes was screened using the Cox-Proportional Hazards (Cox-PH) model using the penalized package (version 0.9--50) in R ([@b32-ol-0-0-11575]). The optimal parameter of 'lambda' in the Cox-PH model was calculated through 1,000 cross-validation likelihoods (cvl) ([@b33-ol-0-0-11575]).

The risk score prognostic prediction system was constructed combining the Cox-PH prognosis coefficients and methylation levels of the selected optimized genes. The resultant formula was: Risk score=∑coef ~gene~ × Methylation ~gene~ where Coef~gene~ and Methylation~gene~ represented regression coefficient and gene methylation levels, respectively.

The risk scores of samples in the TCGA, E-MTAB-5008 and E-MTAB-5571 datasets were calculated and stratified into high and low risk groups according to the median risk scores. Kaplan-Meier (KM) survival curves ([@b34-ol-0-0-11575]) of the high and low samples were plotted using the survival package, which were compared with the prognosis of all samples. The area under the receiver operating characteristic (ROC) curve (AUC) was compared, also using the survival package.

### Correlation analysis between independent prognostic factors and risk score prognostic prediction system

Using the Cox regression analysis in the survival package ([@b31-ol-0-0-11575]), independent clinical prognostic factors were screened. Next, the relations between collected factors and the risk score prognostic prediction system were analyzed using KM curves.

Results
=======

### Screening of DMGs

Median survival time of samples in the training datasets was 17.09±15.22 months, which is consistent with the time reported in PC ([@b35-ol-0-0-11575]). There were 13,903 methylation sites containing CpG islands in the training dataset. In TCGA training dataset, based on the predefined method for grouping, each less favorable and more favorable prognosis group had 19 samples, and a total of 1,067 DMGs between the two groups were identified ([Fig. 1](#f1-ol-0-0-11575){ref-type="fig"}).

As shown in the Log2 Kernel density curve of the DMGs, 74.98% (800/1,067) of DMGs were significantly hypomethylated and 25.02% (267/1,067) were significantly hypermethylated in the good prognostic group ([Fig. 1B](#f1-ol-0-0-11575){ref-type="fig"}). The cluster heatmap of the DMGs suggested that the samples with different prognoses in the TCGA dataset exhibited different methylation levels ([Fig. 1C](#f1-ol-0-0-11575){ref-type="fig"}). Furthermore, as the feature factors had different weights in the calculation process for heatmap analysis, there was a slight crossover between good and bad prognosis samples.

Among the CpGs in the 1,067 DMGs, 309, 321, 118, 44, 185 and 90 CpGs were separately located in transcription start site areas, body areas, 5′untranslated regions (UTR), 3′UTR regions, promoter regions and the first exon regions (data not shown). The top 20 DMGs with smaller FDR values were screened and presented in [Table I](#tI-ol-0-0-11575){ref-type="table"}.

### Identification of co-methylated genes based on WGCNA

A total of 10 modules were identified ([Fig. 2A](#f2-ol-0-0-11575){ref-type="fig"}) and the detailed information of each module is listed in [Table II](#tII-ol-0-0-11575){ref-type="table"}. CpG island genes in 9 modules showed significant a association with methylation levels (P\<0.05; correlation coefficients, 0.226--0.729; average correlation coefficient, 0.7742; [Table II](#tII-ol-0-0-11575){ref-type="table"}). The identified DMGs were mapped into each module and their distribution in the modules is shown in [Fig. 2B](#f2-ol-0-0-11575){ref-type="fig"}. Two modules were identified as differentially expressed CpG gene enriched modules, black module (comprised of 90 DMGs) and the turquoise module (comprised of 394 DMGs), in which the CpG genes were significantly associated with methylations. The DMGs in these two modules were significantly enriched in 18 GO_Biology Process (BP; such as 'neuron differentiation'), 7 GO_cellular component (CC; such as 'integral to plasma membrane'), and 9 GO_molecular function (MF; such as 'sequence-specific DNA binding') terms ([Table III](#tIII-ol-0-0-11575){ref-type="table"}) and were predominantly associated with transcriptional regulation.

### Correlation analysis of the expression levels and methylation levels of key methylated genes

Overall, the methylation levels and expression levels of the 484 DMGs in the black and turquoise modules were significantly negatively correlated (Cor.=−0.478, P=8.169×10^−5^; [Fig. 2D](#f2-ol-0-0-11575){ref-type="fig"}). A total of 192 DMGs exhibited negative correlation between the expression levels and methylation levels ([Table SI](#SD1-ol-0-0-11575){ref-type="supplementary-material"}).

### Construction of the risk score system

A total of 50 genes among the 192 DMGs were found to be associated with prognosis. Following this, a Cox-PH model was utilized to screen the optimal gene combination. When λ=1.1389, the maximum value of cvl was obtained as −458.1914 ([Fig. 3A](#f3-ol-0-0-11575){ref-type="fig"}). Using λ=1.1389, a 12-gene optimal combination was acquired: CCAAT/enhancer binding protein α (*CEBP*α); histone cluster 1 H4E (*HIST1H4E*); STAM binding protein-like 1, (*STAMBPL1*) phospholipase D3 (*PLD3*); centrosomal protein 55 (*CEP55*); ssDNA binding protein 4 (*SSBP4*); glutamate AMPA receptor subunit 1 (*GRIA1*); switch-associated protein 70 (*SWAP70*); adenylate-cyclase activating polypeptide 1 receptor 1 (*ADCYAP1R1*); yippee-like 3 (*YPEL3*); homeobox C4 (*HOXC4*); and insulin-like growth factor binding protein 1 (*IGFBP1*) ([Fig. 3B](#f3-ol-0-0-11575){ref-type="fig"}; [Table IV](#tIV-ol-0-0-11575){ref-type="table"}). Combined with the prognostic coefficients of these 12 optimal genes, the following risk score system was constructed (cg is the methylation ID for corresponding genes.).

Risk score=(−0.4701559) × Methylation ~cg22250546~ + (1.461097) × Methylation ~cg23066982~ + (−0.1543761) × Methylation ~cg23264429~ + (0.2124921) × Methylation ~cg25509871~ + (−0.7063513) × Methylation ~cg25827255~+ (0.1268035) × Methylation ~cg25902939~ + (−2.4642526) × Methylation ~cg26343183~+ (−0.4583647) × Methylation ~cg26645401~ +(0.0652014) xMethylation ~cg27076139~+ (0.2566994) × Methylation ~cg27106909~ + (0.7707755) × Methylation ~cg27138204~ + (0.172493) × Methylation ~cg27447599.~

According to the median of the risk scores of the samples in the TCGA dataset, the samples were divided into high and low risk groups. For the TCGA dataset, the comparison between the actual overall survival and risk score system predicting survival of the risk groups was performed and the AUC was 0.976 ([Fig. 4A](#f4-ol-0-0-11575){ref-type="fig"}). Moreover, the risk score system was validated in the E-MTAB-5008 ([Fig. 4B](#f4-ol-0-0-11575){ref-type="fig"}) and E-MTAB-5571 ([Fig. 4C](#f4-ol-0-0-11575){ref-type="fig"}) datasets and the AUCs were 0.919 and 0.924, respectively. The TCGA, E-MTAB-5008 and E-MTAB-5571 datasets had consistent results and all the samples in low risk group had improved survival.

### Correlation analysis between independent prognostic factors and risk groups

The clinical information of 168 samples in the TCGA dataset was statistically analyzed, and pathological tumor-node-metastases (TNM) staging system ([@b36-ol-0-0-11575]), radiotherapy and risk status were identified as independent prognostic factors ([Table V](#tV-ol-0-0-11575){ref-type="table"}). Survival status of high and low risk groups with different pathological N stages (N0 vs. N1) and treatment with radiotherapy (treatment with radiotherapy vs. without radiotherapy) were compared ([Fig. 5](#f5-ol-0-0-11575){ref-type="fig"}).

Discussion
==========

The mechanisms underlying tumor development and progression of PAAD are complex, and influencing factors include epigenetic regulation of gene expression, epigenetic silencing of genes, oncogenic/tumor suppressor gene mutation, telomere alteration, genomic instability and DNA methylation ([@b37-ol-0-0-11575]--[@b40-ol-0-0-11575]). The present study aimed to identify potential important key methylated genes in PAAD. A total of 1,067 DMGs were identified in the less favorable prognosis and more favorable prognosis groups. From the 10 modules identified by WGCNA, the black (involving 90 DMGs) and turquoise (involving 394 DMGs) modules, in which the CpG genes were significantly associated with methylations, were selected for further analysis. For the 484 DMGs involved in the two key modules, 18 GO_BP, 7 GO_CC and 9 GO_MF terms were enriched. There were 192 DMGs associated with prognosis (less favorable or more favorable). Correlation analysis indicated that the expression levels and methylation levels of 192 DMGs among the 484 DMGs were negatively correlated. Furthermore, 50 prognosis-associated genes were further screened from the 192 DMGs. After a 12-gene optimal combination (*CEBPA, HIST1H4E, STAMBPL1, PLD3, CEP55, SSBP4, GRIA1, SWAP70, ADCYAP1R1, YPEL3, HOXC4* and *IGFBP1*) was identified, the risk score system was constructed and validated in the TCGA, E-MTAB-5008 and E-MTAB-5571 datasets. In addition, pathological N category, radiotherapy and risk status were found to be independent prognostic factors.

It is demonstrated that upregulation of CCAAT/enhancer binding protein (C/EBP) beta (C/EBPβ), encoded by *CEBPB*, could restore the anti-cancer functions of Menin in PC ([@b41-ol-0-0-11575]) The inadequate cytoplasmic localization and abnormal silencing of *C/EBP* results in its dysfunction, and thus, *C/EBP* may serve as a novel suppressor in PC cells ([@b42-ol-0-0-11575]). Downregulated *C/EBPα* induced by lysine (K)-specific demethylase 6B (*KDM6B*) promotes the aggressiveness of pancreatic ductal adenocarcinoma (PDAC) cells, indicating that the *KDM6B-C/EBPα* axis is associated with the progression of PDAC ([@b43-ol-0-0-11575],[@b44-ol-0-0-11575]). Histone H3 modification affects the gene expression and promoter methylation of *MUC2*, which may be critical for the prognostic prediction of patients with PC ([@b45-ol-0-0-11575]). The mRNA expression levels of histone H4 is lowered by polyamide-chlorambucil conjugate (1R-Chl) in the MIA PaCa-2 PC cell line and histone H4 genes have elevated histone acetylation in tumor cells ([@b46-ol-0-0-11575]). Therefore, *CEBPA* and *HIST1H4E* may be critical for the survival of PAAD patients.

*STAMBPL1* affects the activation of *NF*-κB through mediating the stability and localization of Tax ([@b47-ol-0-0-11575]) and *NF*-κB blockade can inhibit the oncogenicity and metastasis of PC cells ([@b48-ol-0-0-11575]). Overexpression of *CEP55* can promote PC cell aggressiveness via activation of the NF-κB pathway; therefore, *CEP55* may be a prognostic factor and therapeutic target for patients with PC ([@b49-ol-0-0-11575]). Downregulated expression of *YPEL1* in PAAD samples is associated with perineural invasion and survival prognosis, thus *YPEL1* may serve a role in the malignant transformation of pancreatic tissues ([@b50-ol-0-0-11575]). Low *IGFBP1* plasma levels have a more notable influence in non-smoking patients with PC and predicts an increased risk of PC ([@b51-ol-0-0-11575]). These data suggest that *STAMBPL1, CEP55, YPEL3* and *IGFBP1* may be associated with the prognosis of patients with PAAD.

Although *PLD3, SSBP4, GRIA1, SWAP70* and *ADCYAP1R1* do not have reported associations with PAAD to the best of our knowledge, their influence on other types of human cancer have been reported. Elevated expression and activity of *PLD* is detected in multiple types of cancer, such as gastric, colorectal, renal, stomach, lung and breast cancers ([@b52-ol-0-0-11575]), and *PLD* serves a role in mediating cell proliferation, cell transition, survival signaling and tumor progression ([@b53-ol-0-0-11575]). *SSBP2* is a tumor suppressor gene and the disruption of *SSBP2*-associated pathways may be involved in the malignant transformation of various tissues ([@b54-ol-0-0-11575]). *GRIA1* is involved in glutamate receptor signaling, which is an epigenetic marker for overall mortality rate of basal-like urothelial carcinomas ([@b55-ol-0-0-11575]). The oncogene *SWAP70* functions in regulating actin rearrangement in basal-like bladder cancer ([@b55-ol-0-0-11575]) and serves a role in the transformation-associated signaling pathway ([@b56-ol-0-0-11575]). The promoter hypermethylation level of *ADCYAP1* is associated with cervical cancer development and is considered as a promising methylation marker for the early detection of cervical cancer ([@b57-ol-0-0-11575]). Therefore, *PLD3, SSBP4, GRIA1, SWAP70* and *ADCYAP1R1* may also be associated with the prognosis of patients with PAAD.

In the present study comprehensive bioinformatics analysis of PAAD samples was performed to identify prognosis-associated genes and to construct a risk score prognostic prediction system. All findings were obtained from relatively small-sized cohorts and thus require further experimental validation. Additionally, the patient cohort samples in the three datasets may exert different clinical features, such as disease stage, historical treatment and demographics, which should be carefully compared in further studies.

In conclusion, 1,067 DMGs were identified and a 12-gene optimal combination consisting of *CEBPA, HIST1H4E, STAMBPL1, PLD3, CEP55, SSBP4, GRIA1, SWAP70, ADCYAP1R1, YPEL3, HOXC4* and *IGFBP1* was obtained. This 12-gene risk score prognostic prediction system may be valuable for predicting the prognosis of patients with PAAD.

Supplementary Material
======================

###### Supporting Data

Not applicable.

Funding
=======

No funding was received.

Availability of data and materials
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

DD conceived the study design and performed manuscript drafting, SY was responsible for data collection and analysis and JZ performed data interpretation and manuscript writing. All authors read and approved the final manuscript.

Ethical approval and consent to participate
===========================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Volcano plot, density curve and cluster heatmap of DMGs. (A) Volcano plot showing the FC of each identified gene. Red dots, DMGs; horizontal dashed line, FDR \<0.05; vertical dashed lines, \|log FC\| \>0.263. (B) Kernel density curve showing that 74.98% of the DMGs are significant hypomethylated in the good prognostic group. (C) Bidirectional hierarchical cluster heatmap. Orange and purple samples strips separately represent the samples in good and bad prognostic groups, respectively; color changes from green to red represent methylation level changes from low to high, respectively. DMGs, differentially methylated genes; FDR, false discovery rate; FC, fold change.](ol-20-01-0085-g00){#f1-ol-0-0-11575}

![Results of Weighted Gene Co-expression Network Analysis. (A) Module partition tree. (B) Mapping results of the DMGs into the identified modules. Numbers in the brackets represent genes in this module. (C) Histogram of fold enrichment of the modules. (D) Scatter diagram showing the overall correlation between the methylation levels and expression levels of the 484 DMGs. Red line, trend line of point distribution. \*Represents the modules with significantly enriched methylated genes (P\<0.05). DMGs, differentially methylated genes; cor., correlation coefficient.](ol-20-01-0085-g01){#f2-ol-0-0-11575}

![Selection curve and coefficient distribution diagram. (A) Selection curve of lambda (the junction indicates that the maximum value of cvl is −458.1914 when λ=1.1389) (B) The coefficient distribution diagram of the genes implicated in the optimal gene combination.cvl, cross validation likelihood; prof\$ in Y-axis indicated the p value using the predictive model, and in X-axis indicated the lambda value using the predictive model; CEBPA, CCAAT/enhancer binding protein α; HIST1H4E, histone cluster 1 H4E; STAMBPL1, STAM binding protein-like 1; PLD3, phospholipase D3; CEP55, centrosomal protein 55; SSBP4, ssDNA binding protein 4; GRIA1, glutamate AMPA receptor subunit 1; SWAP70, switch-associated protein 70; ADCYAP1R1, adenylate-cyclase activating polypeptide 1 receptor 1; YPEL3, yippee-like 3; HOXC4, homeobox C4; IGFBP1, insulin-like growth factor binding protein 1.](ol-20-01-0085-g02){#f3-ol-0-0-11575}

![KM curves and AUC under the ROC curve. (A) KM curve (left) and ROC curve (right) for TCGA dataset. (B) KM curve (left) and ROC curve (right) for E-MTAB-5008 dataset. (C) KM curve (left) and ROC curve (right) for E-MTAB-5571 dataset. KM, Kaplan-Meier; HR, hazard ratio; TCGA, The Cancer Genome Atlas; ROC, receiver operating characteristic; AUC, area under the curve.](ol-20-01-0085-g03){#f4-ol-0-0-11575}

![KM curves for high- and low-risk groups with different TNM stages and radiotherapy treatment status. (A) KM curves showing the correlations of pathological N0 (left) and pathological N1 (right) with risk groups. (B) KM curves showing the correlations between without radiotherapy (left) or with radiotherapy (right) and risk groups. KM, Kaplan-Meier; HR, hazard ratio; T, tumor stage; N, node stage; M, metastasis stage.](ol-20-01-0085-g04){#f5-ol-0-0-11575}

###### 

Top 20 differentially methylated genes with significance.

  Methylation loci   Chr.    Position    Genes        Location   β-bad    β-good   Effect    P-value                                                   FDR
  ------------------ ------- ----------- ------------ ---------- -------- -------- --------- --------------------------------------------------------- -------------
  cg24902557         chr14   104786509   *BTBD6*      Promoter   0.3277   0.0926   −1.8239   5.24×10^−7[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   4.25×10^−6^
  cg27106909         chr16   30014398    *YPEL3*      Promoter   0.3150   0.1325   −1.2489   8.88×10^−7[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   7.20×10^−6^
  cg25207224         chr6    34319167    *HMGA1*      Body       0.5645   0.7547   0.4188    5.80×10^−6[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   4.70×10^−5^
  cg27543607         chr16   88289602    *CDK10*      3′UTR      0.6878   0.5288   −0.3791   6.59×10^−6[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   5.34×10^−5^
  cg27058889         chr1    55237413    *BSND*       1stExon    0.5441   0.7574   0.4772    6.71×10^−6[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   5.44×10^−5^
  cg21197594         chr9    139776802   *EHMT1*      Body       0.7238   0.4881   −0.5683   9.65×10^−6[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   7.82×10^−5^
  cg26789779         chr5    37875700    *GDNF*       TSS200     0.3598   0.1482   −1.2801   9.92×10^−6[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   8.04×10^−5^
  cg23066982         chr6    26312442    *HIST1H4E*   Promoter   0.2446   0.0759   −1.6886   1.12×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   9.08×10^−5^
  cg27575890         chr22   35237104    *EIF3D*      Body       0.3592   0.2527   −0.5075   1.16×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   9.44×10^−5^
  cg24864161         chr22   48870409    *MOV10L1*    TSS200     0.2022   0.0689   −1.5531   1.21×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   9.84×10^−5^
  cg24460144         chr5    149550073   *SLC6A7*     5′UTR      0.3093   0.1822   −0.7637   1.43×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.16×10^−4^
  cg27576241         chr1    153301194   *ADAM15*     Body       0.5530   0.4002   −0.4667   1.50×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.21×10^−4^
  cg23930825         chr6    43721343    *RSPH9*      Body       0.3502   0.2102   −0.7365   1.74×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.41×10^−4^
  cg26432961         chr6    41625040    *FOXP4*      5′UTR      0.7897   0.5080   −0.6365   1.79×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.45×10^−4^
  cg27626790         chr7    150305686   *KCNH2*      Body       0.2627   0.1002   −1.3909   1.80×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.45×10^−4^
  cg09730123         chr16   1767949     *SPSB3*      Body       0.4173   0.3468   −0.2670   1.81×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.47×10^−4^
  cg25499067         chr8    23615933    *NKX2-6*     Body       0.2310   0.1187   −0.9606   1.97×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.60×10^−4^
  cg25902939         chr19   18405350    *SSBP4*      Body       0.4202   0.2254   −0.8986   2.01×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.63×10^−4^
  cg27390009         chr17   18091226    *FLII*       Body       0.5073   0.3645   −0.4768   2.05×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.66×10^−4^
  cg24542766         chr22   38043478    *RPL3*       Body       0.3924   0.2856   −0.4580   2.10×10^−5[a](#tfn1-ol-0-0-11575){ref-type="table-fn"}^   1.70×10^−4^

P\<0.001. cg indicates methylation ID of a gene; chr., chromosome; Position, position of the methylation sites in chromosomes; Location, location of CpG islands; β-bad, the average methylation level β in bad prognostic groups; β-good, the average methylation level β in good prognostic groups; Effect, log~2~ fold change; FDR, false discovery rate; TSS, transcription start site; UTR, untranslated region.

###### 

A total of 10 modules identified by weighted gene co-expression network analysis.

  Modules     Count of CpGs   Correlation   P~corr~        DMGs   Enrichment fold (95% CI)   P~hyper~
  ----------- --------------- ------------- -------------- ------ -------------------------- --------------
  Black       159             0.703         1.01×10^−13^   90     3.481 (2.622--4.599)       2.20×10^−16^
  Blue        427             0.587         1.68×10^−4^    63     0.908 (0.676--1.202)       5.37×10^−1^
  Brown       364             0.551         2.23×10^−3^    10     0.169 (0.0799--0.317)      4.83×10^−13^
  Green       352             0.616         6.05×10^−2^    12     0.209 (0.107--0.374)       3.49×10^−11^
  Grey        574             0.226         1.32×10^−1^    48     0.514 (0.371--0.701)       5.31×10^−6^
  Magenta     90              0.729         9.47×10^−16^   23     1.572 (0.941--2.529)       7.38×10^−2^
  Pink        138             0.679         1.44×10^−8^    6      0.267 (0.0961--0.601)      2.88×10^−4^
  Red         191             0.308         6.69×10^−7^    1      0.0322 (0.000814--0.182)   3.26×10^−11^
  Turquoise   1344            0.687         1.72×10^−6^    394    1.803 (1.564--2.077)       4.11×10^−16^
  Yellow      359             0.609         4.27×10^−6^    3      0.0514 (0.0105--0.152)     2.20×10^−16^

DMGs, differentially methylated genes; CI, confidence interval; P~corr~, P-value for correlation; P~hyper~, P-value for hypermethylation.

###### 

Functional terms enriched for the 484 differentially methylated genes involved in black or turquoise modules.

  A, Biological process                                                                                                                    
  ----------------------------------------------------------------- ----------- ---------------------------------------------------------- --------------
  GO:0030182-neuron differentiation                                 40          1.79×10^−10[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^   3.13×10^−7^
  GO:0006355-regulation of transcription, DNA-dependent             95          4.27×10^−10[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^   7.45×10^−7^
  GO:0051252-regulation of RNA metabolic process                    96          6.29×10^−10[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^   1.10×10^−6^
  GO:0007423-sensory organ development                              27          1.46×10^−9[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.55×10^−6^
  GO:0007389-pattern specification process                          28          8.94×10^−9[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.56×10^−5^
  GO:0045165-cell fate commitment                                   20          1.20×10^−8[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.10×10^−5^
  GO:0048568-embryonic organ development                            22          1.59×10^−8[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.77×10^−5^
  GO:0048598-embryonic morphogenesis                                28          1.66×10^−7[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.90×10^−4^
  GO:0007267-cell-cell signaling                                    40          9.79×10^−7[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.71×10^−3^
  GO:0006928-cell motion                                            34          1.66×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.90×10^−3^
  GO:0045449-regulation of transcription                            111         2.63×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    4.60×10^−3^
  GO:0003002-regionalization                                        20          3.02×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    5.27×10^−3^
  GO:0007610-behavior                                               33          3.54×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    6.18×10^−3^
  GO:0048666-neuron development                                     27          3.76×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    6.57×10^−3^
  GO:0031328-positive regulation of cellular biosynthetic process   42          4.11×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    7.17×10^−3^
  GO:0009891-positive regulation of biosynthetic process            42          5.85×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.02×10^−2^
  GO:0016477-cell migration                                         23          1.16×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.02×10^−2^
  GO:0019226-transmission of nerve impulse                          26          1.97×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    3.45×10^−2^
                                                                                                                                           
  **B, Cellular component**                                                                                                                
                                                                                                                                           
  **Term**                                                          **Count**   **P-Value**                                                **FDR**
                                                                                                                                           
  GO:0005887-integral to plasma membrane                            59          9.12×10^−7[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.21×10^−3^
  GO:0031226\~intrinsic to plasma membrane                          59          1.89×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.50×10^−3^
  GO:0044459-plasma membrane part                                   90          2.93×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    3.88×10^−3^
  GO:0034703-cation channel complex                                 15          6.78×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    8.98×10^−3^
  GO:0034705-potassium channel complex                              12          1.11×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.48×10^−2^
  GO:0008076-voltage-gated potassium channel complex                12          1.11×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.48×10^−2^
  GO:0034702-ion channel complex                                    18          1.99×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.64×10^−2^
                                                                                                                                           
  **C, Molecular function**                                                                                                                
                                                                                                                                           
  **Term**                                                          **Count**   **P-value**                                                **FDR**
                                                                                                                                           
  GO:0043565-sequence-specific DNA binding                          58          4.65×10^−16[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^   6.55×10^−13^
  GO:0003700-transcription factor activity                          74          4.42×10^−15[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^   6.52×10^−12^
  GO:0030528-transcription regulator activity                       85          3.53×10^−10[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^   5.18×10^−7^
  GO:0003677-DNA binding                                            109         2.11×10^−8[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    3.09×10^−5^
  GO:0022836-gated channel activity                                 25          6.95×10^−6[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.02×10^−2^
  GO:0005261-cation channel activity                                23          1.01×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    1.48×10^−2^
  GO:0015267-channel activity                                       29          1.41×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.07×10^−2^
  GO:0022803-passive transmembrane transporter activity             29          1.48×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    2.18×10^−2^
  GO:0005216-ion channel activity                                   27          3.37×10^−5[a](#tfn3-ol-0-0-11575){ref-type="table-fn"}^    4.94×10^−2^

P\<0.001. GO, gene ontology; FDR, false discovery rate.

###### 

Information of the 12 optimal genes.

  Methylation ID   Gene          Chr.    Position    Location   Coefficient   Hazard ratio   P-value
  ---------------- ------------- ------- ----------- ---------- ------------- -------------- ---------------------------------------------------------
  cg22250546       *CEBPA*       chr19   38483210    Promoter   −0.4701559    0.197          2.01×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg23066982       *HIST1H4E*    chr6    26312442    Promoter   1.461097      1.228          4.11×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg23264429       *STAMBPL1*    chr10   90631983    5′UTR      −0.1543761    0.369          4.53×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg25509871       *PLD3*        chr19   45563397    5′UTR      0.2124921     1.082          4.40×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg25827255       *CEP55*       chr10   95246749    Promoter   −0.7063513    0.129          2.04×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg25902939       *SSBP4*       chr19   18405350    Body       0.1268035     1.139          4.45×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg26343183       *GRIA1*       chr5    152988914   Body       −2.4642526    0.276          1.33×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg26645401       *SWAP70*      chr11   9643090     Body       −0.4583647    0.272          2.02×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg27076139       *ADCYAP1R1*   chr7    31058243    TSS1500    0.0652014     1.014          1.35×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg27106909       *YPEL3*       chr16   30014398    Promoter   0.2566994     1.294          4.32×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg27138204       *HOXC4*       chr12   52732367    5′UTR      0.7707755     1.679          1.58×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^
  cg27447599       *IGFBP1*      chr7    45894465    TSS200     0.172493      1.193          2.18×10^−2[a](#tfn4-ol-0-0-11575){ref-type="table-fn"}^

P\<0.01. chr, chromosome; coef, correlation coefficient; UTR, untranslated region; TSS, transcription start site.

###### 

The results for screening independent prognostic factors.

                                                            Univariate cox   Multivariate cox                                                                                       
  ------------------------------------------- ------------- ---------------- ------------------ --------------------------------------------------------- --------- --------------- ---------------------------------------------------------
  Age, years, mean ± sd                       64.89±11.24   1.029            1.008--1.049       5.83×10^−3[b](#tfn6-ol-0-0-11575){ref-type="table-fn"}^   1.019     0.997--1.0413   9.46×10^−2^
  Sex                                                       0.919            0.605--1.394       6.89×10^−1^                                               Unknown   Unknown         Unknown
    Male                                      94                                                                                                                                    
    Female                                    75                                                                                                                                    
  Pathologic M                                              1.491            0.457--4.858       5.05×10^−1^                                               Unknown   Unknown         Unknown
    M0                                        79                                                                                                                                    
    M1                                        4                                                                                                                                     
    Unknown                                   85                                                                                                                                    
  Pathologic N                                              2.156            1.276--3.643       3.31×10^−3[b](#tfn6-ol-0-0-11575){ref-type="table-fn"}^   2.12      1.139--3.947    1.19×10^−2[a](#tfn5-ol-0-0-11575){ref-type="table-fn"}^
    N0                                        45                                                                                                                                    
    N1                                        119                                                                                                                                   
    Unknown                                   4                                                                                                                                     
  Pathologic T                                              1.711            1.116--2.622       1.35×10^−2[a](#tfn5-ol-0-0-11575){ref-type="table-fn"}^   1.221     0.576--2.585    6.03×10^−1^
    T1                                        8                                                                                                                                     
    T2                                        19                                                                                                                                    
    T3                                        136                                                                                                                                   
    T4                                        4                                                                                                                                     
    Unknown                                   1                                                                                                                                     
  Pathologic stage                                          1.488            1.040 -- 2.129     3.12×10^−2[a](#tfn5-ol-0-0-11575){ref-type="table-fn"}^   0.996     0.473--2.096    9.92×10^−1^
    I                                         20                                                                                                                                    
    II                                        138                                                                                                                                   
    III                                       5                                                                                                                                     
    IV                                        4                                                                                                                                     
    Unknown                                   1                                                                                                                                     
  Pathologic grade                                          1.538            1.148--2.061       3.76×10^−3[b](#tfn6-ol-0-0-11575){ref-type="table-fn"}^   1.366     0.993--1.879    5.56×10^−2^
    1                                         30                                                                                                                                    
    2                                         88                                                                                                                                    
    3                                         47                                                                                                                                    
    4                                         2                                                                                                                                     
    Unknown                                   1                                                                                                                                     
  History of alcohol usage                                  1.099            0.688--1.757       6.92×10^−1^                                               Unknown   Unknown         Unknown
    Yes                                       96                                                                                                                                    
    No                                        56                                                                                                                                    
  History of alcohol usage                                  1.099            0.688--1.757       6.92×10^−1^                                               Unknown   Unknown         Unknown
    Unknown                                   16                                                                                                                                    
  Tobacco history                                           1.117            0.874--1.427       3.75×10^−1^                                               Unknown   Unknown         Unknown
    Never                                     61                                                                                                                                    
    Reform                                    56                                                                                                                                    
    Current                                   19                                                                                                                                    
    Unknown                                   32                                                                                                                                    
  Chronic pancreatitis history                              1.101            0.524--2.314       7.99×10^−1^                                               Unknown   Unknown         Unknown
    Yes                                       117                                                                                                                                   
    No                                        13                                                                                                                                    
    Unknown                                   38                                                                                                                                    
  Diabetes history                                          0.903            0.509--1.602       7.27×10^−1^                                               Unknown   Unknown         Unknown
    Yes                                       36                                                                                                                                    
    No                                        99                                                                                                                                    
    Unknown                                   33                                                                                                                                    
  Radiotherapy                                              0.529            0.302--0.928       2.39×10^−2[a](#tfn5-ol-0-0-11575){ref-type="table-fn"}^   0.502     0.279--0.906    3.78×10^−2[a](#tfn5-ol-0-0-11575){ref-type="table-fn"}^
    Yes                                       38                                                                                                                                    
    No                                        112                                                                                                                                   
    Unknown                                   18                                                                                                                                    
  Recurrence                                                1.558            0.951--2.552       7.59×10^−2^                                               Unknown   Unknown         Unknown
    Yes                                       40                                                                                                                                    
    No                                        102                                                                                                                                   
    Unknown                                   26                                                                                                                                    
  Risk status                                               2.453            1.578--3.815       3.93×10^−5[c](#tfn7-ol-0-0-11575){ref-type="table-fn"}^   2.146     1.289--3.571    3.31×10^−3[b](#tfn6-ol-0-0-11575){ref-type="table-fn"}^
    High                                      84                                                                                                                                    
    Low                                       84                                                                                                                                    
  Dead                                                      Unknown          Unknown            Unknown                                                   Unknown   Unknown         Unknown
    Death                                     88                                                                                                                                    
    Alive                                     80                                                                                                                                    
  Overall survival time, months, mean ± sd)   17.09±15.22   Unknown          Unknown            Unknown                                                   Unknown   Unknown         Unknown

P\<0.05

P\<0.01

P\<0.001. TCGA, The Cancer Genome Atlas; HR, Hazard Ratio; CI, confidence interval; sd, standard deviation; T, tumor stage; N, node stage; M, metastasis stage.
